This study is for people aged 18 to 50 with sickle cell disease (SCD). It will test a new drug, GSK4172239D, to see if it is safe and how it behaves in the body compared to a placebo (a harmless pill with no medicine). The study has three parts: Screening, Treatment, and Follow-up. During Screening, participants will be checked to make sure they can join. In the Treatment period, they will be randomly given either the GSK4172239D drug or the placebo. This is a **single-dose** and **dose-escalation** study, meaning participants will receive one dose and the dose amount may increase. Some participants will also take the drug with food in a special group called the Food Effect Cohort.
- Time Commitment: Includes Screening, Treatment, and Follow-up periods.
- Participation: Randomized to receive either the study drug or placebo.
- Eligibility: Must have SCD and meet specific health criteria.
How understandable was the trial content above?
Hard to understand
Easy to understand